Agenus Inc. (AGEN) News

Agenus Inc. (AGEN): $2.13

-0.11 (-4.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add AGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 395

in industry

Filter AGEN News Items

AGEN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGEN News Highlights

  • AGEN's 30 day story count now stands at 15.
  • Over the past 20 days, the trend for AGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about AGEN are AZN, III and MD.

Latest AGEN News From Around the Web

Below are the latest news stories about AGENUS INC that investors may wish to consider to help them evaluate AGEN as an investment opportunity.

7 Penny Stocks That Actually Have a Buy Rating

Penny stocks are always a risky proposition.

Alex Sirois on InvestorPlace | September 19, 2022

Agenus (AGEN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Agenus (AGEN) closed at $2.31, marking a -1.28% move from the previous day.

Yahoo | September 19, 2022

Is Trending Stock Agenus Inc. (AGEN) a Buy Now?

Agenus (AGEN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Yahoo | September 19, 2022

J&J (JNJ) Announces $5B Stock Repurchase Program, Stock Up

J&J (JNJ) to buy back $5 billion worth of shares. It also reaffirms its financial guidance for 2022.

Yahoo | September 15, 2022

Key Factors Driving Merck's (MRK) Outperformance This Year

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

Yahoo | September 14, 2022

Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA

FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.

Yahoo | September 12, 2022

Agenus Initiates Botensilimab Phase 2 ACTIVATE Trials in Advanced MSS Colorectal Cancer and Advanced Melanoma

Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapiesBotensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust clinical activity in nine treatment-resistant tumor types, including microsatellite stable colorectal cancer LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to canc

Yahoo | September 12, 2022

Agenus Makes Senior Regulatory and Clinical Appointments

Patricia Carlos named Chief Regulatory, Quality, and Safety OfficerTodd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the appointment of Patricia Carlos as Chief Regulatory, Quality, and Safety Officer; Todd Yancey, MD as Gl

Yahoo | September 12, 2022

Pfizer (PFE) Streptococcus Jab Gets FDA's Breakthrough Tag

Pfizer (PFE) gets Breakthrough Therapy Designation for GBS vaccine candidate, GBS6, based on an interim analysis of a phase II study.

Yahoo | September 8, 2022

GSK's NDA for Daprodustat to be Reviewed by an FDA Panel

GSK's regulatory applications for daprodustat are based on data from the ASCEND phase III program, consisting of five studies.

Yahoo | September 7, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3874 seconds.